AI-generated analysis
H.I.G. Capital’s acquisition of SkinCure Oncology positions the private equity firm to capitalize on the growing demand for advanced oncological treatment solutions in the U.S. market. By acquiring a leading provider of image-guided superficial radiation therapy (IG-SRT), H.I.G. enhances its portfolio with a differentiated technology that addresses unmet clinical needs and offers superior patient outcomes compared to traditional radiation therapies. This acquisition bolsters H.I.G.’s strategic healthcare investments by expanding into the high-growth oncology segment, which is anticipated to benefit from ongoing advancements in precision medicine and supportive government policies.
Marathon Asset Management provided a senior secured credit facility to finance the deal, leveraging its integrated investment platform to offer tailored financing solutions for mid-market transactions. Although specific financial details were not disclosed, Marathon’s involvement suggests that H.I.G. was able to secure favorable debt terms to support this strategic healthcare acquisition. The use of a structured financing package likely reflects H.I.G.’s commitment to optimizing capital allocation and ensuring the long-term viability of SkinCure Oncology within its portfolio.
The deal reshapes the competitive landscape in the IG-SRT market, potentially limiting entry for other players seeking to penetrate this specialized segment. With SkinCure Oncology’s robust technology platform and established patient base, H.I.G.’s acquisition creates a formidable competitor that could drive consolidation or innovation among existing providers of oncological solutions. This strategic move also positions H.I.G. as an influential investor in the broader healthcare ecosystem, signaling its intention to focus on high-growth sub-sectors with significant therapeutic potential.
Looking ahead, the integration process will be crucial for realizing synergies between SkinCure Oncology and other assets within H.I.G.’s portfolio. Key challenges may include harmonizing operational processes, integrating R&D efforts to accelerate product development cycles, and maintaining regulatory compliance across a larger enterprise. Successfully navigating these hurdles could unlock growth opportunities through expanded clinical applications of IG-SRT technology and potential partnerships with pharmaceutical firms seeking innovative delivery methods for oncological treatments.
Transaction overview
H.I.G. Capital acquired SkinCure Oncology on November 4, 2024, securing full ownership of the U.S.-based healthcare provider specializing in image-guided superficial radiation therapy (IG-SRT). The transaction details were not disclosed, including the purchase price and key terms.
Deal structure and financing
Marathon Asset Management provided a senior secured credit facility to finance H.I.G. Capital's acquisition of SkinCure Oncology. While the exact equity-debt split remains undisclosed, Marathon is known for offering financings ranging from $50 million to $250 million through its Private Credit platform. The company emphasized the collaborative effort between its Healthcare Finance and Direct Lending teams in providing a tailored financing solution for H.I.G. Capital.
Strategic context
H.I.G. Capital’s acquisition of SkinCure Oncology underscores the firm's strategic focus on expanding its presence within innovative healthcare technologies, particularly those that enhance patient outcomes through advanced radiation therapy solutions. The deal highlights the growing demand for non-invasive cancer treatments and reflects a broader trend in private equity investment towards specialized medical devices and therapies. For SkinCure Oncology, divestiture to H.I.G. Capital allows the company to benefit from substantial capital injections and operational support, enabling further development of its IG-SRT technology.
Regulatory path
The acquisition did not require significant regulatory scrutiny given that both entities are based in the United States and the deal value is undisclosed. No specific regulatory filings or remedies were reported. The transaction likely fell under routine review by the Federal Trade Commission (FTC) and/or the Department of Justice (DOJ), but no public announcements regarding these reviews have been made to date.